Steinberg Leigh is identified as a new insider of FibroBiologics, Inc., where Leigh serves as a director. The designation matters to investors because it connects a named board member with the company’s reported insider-position record, while the regulatory record also identifies FibroBiologics under ticker FBLG.
Key Highlights
- The regulatory record was submitted to the U.S. Securities and Exchange Commission.
- The document identifies FibroBiologics, Inc. under ticker FBLG.
- The submission is designated as Form 3, covering a new insider position.
New Insider Position Recorded The
regulatory record was submitted to the U.S. Securities and Exchange Commission. It is designated as Form 3 and concerns a new insider position involving Steinberg Leigh. FibroBiologics, Inc (NASDAQ: FBLG). is identified in the record by ticker FBLG. Steinberg Leigh is described as a director of the company.
FAQs
Q: What is Steinberg Leigh’s role at FibroBiologics?
A: Steinberg Leigh is identified as a director of FibroBiologics, Inc. The regulatory record also classifies Leigh as a new insider of the company.
Q: What does the FibroBiologics Form 3 concern?
A: The Form 3 concerns a new insider position involving Steinberg Leigh. The filing identifies FibroBiologics, Inc. by ticker FBLG and records Steinberg Leigh in connection with the company.
Q: Where was the Steinberg Leigh insider record submitted?
A: The record was submitted to the U.S. Securities and Exchange Commission. It identifies Steinberg Leigh as a FibroBiologics director and new insider.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.